| Bioactivity | RQIK-(Lys-fructosyl)-QTA-(Leu-13C6,15N)-VE is the 13C and 15N labeled compound[1]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | RQIK-(Lys-fructosyl)-QTA-(Leu-13C6,15N)-VE |
| Sequence | Arg-Gln-Ile-Lys-{Lys-fructosyl}-Gln-Thr-Ala-{Leu-13C6,15N}-Val-Glu |
| Shortening | RQIK-{Lys-fructosyl}-QTA-{Leu-13C6,15N}-VE |
| Formula | C5713C6H114N1715NO22 |
| Molar Mass | 1482.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |